One of our sponsors sought to determine the inflammatory status of the subjects in a clinical study following their drug administration. Here, we recommended a Meso Scale Discovery based eight (8) plex pro-inflammatory V-PLEX cytokine/chemokine panel.
This MSD platform based assay utilizes antibody cocktails for the eight analytes in 96 well plate layout towards a reproducible assay with high sensitivity and specificity for these biomarkers. Meso Scale Discovery platform offers bioanalysis with improved sensitivity, limited matrix effects, and broader dynamic range that enables measurement of multiple analytes from a single sample (i.e., multiplexing). Furthermore, the MSD ECL platform offers stability and non-radioactivity with easily conjugated labels. These advantages make MSD a solid alternative to conventional colorimetric methods like ELISA.
Here, we coated the MSD multi-array plate for One hour at room temperature (RT) with a cocktail of capture-antibodies. Next, we prepared standard curves, quality controls, and samples as per FDA bioanalytical method validation and sample analysis regulatory requirements. Later, 1% BSA blocking, standards, QCs, and samples were added to the coated plate, and incubated at RT on a shaker. Afterward, we washed off the excess or unbound proteins in automated plate washers. For detection, our team added SULFO-TAG conjugated antibody and captured the ECL signal on an MSD imager.